|
Details
|
Specifications
|
|---|---|
|
CAS Number
|
3008544-96-2
|
|
Molecular Formula
|
C48H48F2N10O5.1/2Ca.H2O
|
|
Molecular Weight
|
921.02 g/mol.
|
|
Synonyms
|
LY3502970 hemicalcium hydrate
|
|
Chemical Name
|
3-((1S, 2S)-1-(5-((S)-2, 2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one hemi calcium hydrate
|
|
Therapeutic use
|
Type 2 diabetes and obesity
|
|
Status
|
Tech pack available
|
|
Background
|
Orforglipron hemicalcium hydrate is an investigational, once-daily oral, non-peptide GLP-1 receptor agonist designed to treat Type 2 diabetes and obesity. It acts as an agonist, promoting insulin secretion and reducing body weight (up to 5.4 kg in 4 weeks) and HbA1c, without requiring special food or water restrictions.
|
|
Grade
|
In-house
|
|
Polymorph
|
Amorphous
|
|
Storage Temperature
|
Controlled temperature at 2?C ? 8?C
|
Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*
Disclaimer:
The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.
Orforglipron hemicalcium hydrate (CAS 3008544-96-2; synonym LY3502970 hemicalcium hydrate) is an orally active, once-daily, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist developed for the management of type 2 diabetes mellitus and obesity. Unlike injectable peptide-based GLP-1 therapies, orforglipron is a fully synthetic small molecule, enabling convenient oral dosing without the strict food- and water-timing restrictions associated with peptide GLP-1 agonists. This property has made it one of the most significant metabolic-disease molecules of the decade.
With a molecular formula of C₄₈H₄₈F₂N₁₀O₅·½Ca·H₂O and a molecular weight of 921.02 g/mol, the hemicalcium hydrate salt provides the solid-state characteristics required for robust oral solid dosage development. As the molecule advances from late-stage clinical development into its first global regulatory approvals, demand for reliable orforglipron hemicalcium hydrate manufacturers and suppliers has accelerated sharply across both regulated and emerging markets.
Shilpa Pharma Lifesciences is among the leading orforglipron hemicalcium hydrate manufacturers in India, supplying this non-peptide GLP-1 receptor agonist as a bulk active pharmaceutical ingredient to pharmaceutical and biotechnology partners worldwide. Backed by a complete technical package and integrated CDMO capabilities, Shilpa Pharma supports global partners from early development through commercial-scale manufacturing and supply.
Orforglipron hemicalcium hydrate is supplied as a drug substance (bulk API) for use by pharmaceutical and biotechnology manufacturers in the development and production of oral anti-diabetic and anti-obesity formulations. As a once-daily oral GLP-1 receptor agonist, the molecule acts by stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and enhancing satiety, collectively improving glycaemic control (HbA1c reduction) and supporting clinically meaningful weight reduction.
In a development and manufacturing context, the API supports formulation and oral solid dosage (tablet) development, analytical method development and validation, impurity profiling and reference standard qualification, stability and polymorph studies, and scale-up to clinical and commercial supply. The amorphous solid form supplied by Shilpa Pharma is selected to support solubility and bioavailability optimisation during oral dosage form development.
As established orforglipron hemicalcium hydrate suppliers, Shilpa Pharma provides material exclusively to qualified pharmaceutical manufacturers, biotechnology companies, and international trading partners for development and manufacturing use under applicable regulatory frameworks.
As a member of the GLP-1 receptor agonist class, orforglipron’s clinical safety and tolerability profile is broadly consistent with the established GLP-1 class. In clinical studies, the most commonly reported adverse effects have been gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and dyspepsia; these are typically mild to moderate, dose-dependent, and most frequent during dose escalation. Consistent with the class, finished-product labelling carries class-related precautions, including a boxed warning regarding the risk of thyroid C-cell tumours observed in rodent studies. Concomitant use with other GLP-1 receptor agonists is not recommended.
From a handling and occupational-safety standpoint, orforglipron hemicalcium hydrate should be handled by trained personnel using appropriate engineering controls and personal protective equipment in accordance with the product’s Safety Data Sheet (SDS). The API should be stored under controlled refrigerated conditions at 2°C to 8°C, protected from moisture and light, to maintain stability and quality.
This information is provided for scientific and technical reference to pharmaceutical professionals and does not constitute medical advice.
The cost of orforglipron hemicalcium hydrate varies according to order volume, required specifications, packaging, documentation, and delivery destination. As bulk API pricing is project- and quantity-specific, Shilpa Pharma does not publish standard list pricing for this product.
For current orforglipron hemicalcium hydrate pricing, bulk quantity cost estimates, and commercial supply terms, pharmaceutical and biotechnology buyers are invited to contact Shilpa Pharma directly. As trusted orforglipron hemicalcium hydrate suppliers and exporters, our team provides a tailored quotation based on your required quantity, grade, and regulatory documentation needs, along with competitive, cost-effective supply options for both development-scale and commercial-scale requirements.
Shilpa Pharma Lifesciences is one of the most trusted orforglipron hemicalcium hydrate manufacturers in India and a full-scale CDMO partner, supplying high-quality active pharmaceutical ingredients to pharmaceutical and biotech companies across more than 80 countries. For orforglipron hemicalcium hydrate, partners choose Shilpa Pharma for:
Partner with Shilpa Pharma, a trusted orforglipron hemicalcium hydrate manufacturer and exporter, for a dependable, scalable, and cost-effective global source of this API.
Happy Customers
Projects Successfully Completed
Established
PhD Experts Driving R&D Excellence
Team Size
World-Class API Manufacturing Sites
Global Audits Successfully Completed
Comprehensive CDMO Service Offerings
Everything You Need to Know About Shilpa Pharma
Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*
